• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by Aveanna Healthcare Holdings Inc.

    9/9/24 5:16:27 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care
    Get the next $AVAH alert in real time by email
    S-3/A 1 d864759ds3a.htm S-3/A S-3/A

    As filed with the Securities and Exchange Commission on September 9, 2024

    Registration No. 333-281982

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Pre-Effective Amendment No. 1

    To

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    LOGO

    Aveanna Healthcare Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    (State or other jurisdiction of incorporation or organization)

    81-4717209

    (I.R.S. Employer Identification Number)

    400 Interstate North Parkway SE

    Atlanta, GA, 30339

    (770) 441-1580

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Matthew Buckhalter

    Chief Financial Officer

    400 Interstate North Parkway SE

    Suite 1600

    Atlanta, Georgia 30339

    (770) 441-1580

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Drew M. Altman, Esq.

    Win Rutherfurd, Esq.

    Greenberg Traurig, P.A.

    333 S.E. 2nd Avenue

    Suite 4400

    Miami, Florida 33131

    (305) 579-0500

     

     

    Approximate Date of Commencement of Proposed Sale to the Public: From time to time after this Registration Statement becomes effective as determined by market conditions and other factors.

    If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     


    EXPLANATORY NOTE

    This Pre-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-281982) (the “Registration Statement”) is being filed solely for the purpose of including the delaying amendment language set forth on the cover page hereto. This Pre-Effective Amendment No. 1 does not modify any provisions of the prospectus that forms part of the Registration Statement and, accordingly, such prospectus has not been included herein. This Pre-Effective Amendment No. 1 is not intended to amend or delete any part of the Registration Statement except as specifically noted herein.


    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    ITEM 14.

    Other Expenses of Issuance and Distribution

    The expenses of the Registrant in connection with the distribution of the securities being registered hereunder are set forth below and will be borne by the Registrant.

     

    SEC registration fee

       $ 101,942  

    Printing expenses

         *  

    Accounting fees and expenses

         *  

    Legal fees and expenses

         *  
      

     

     

     

    Total

       $ 101,942  
      

     

     

     

     

    *

    To be provided by amendment or as an exhibit to a filing with the Securities and Exchange Commission (the “SEC”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and incorporated herein by reference.

     

    ITEM 15.

    Indemnification of Directors and Officers

    Section 145(a) of the General Corporation Law of the State of Delaware (the “DGCL”) provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

    Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.

    Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.

     

    II-1


    The Registrant’s Second Amended and Restated Certificate of Incorporation (the “Amended Charter”) and the Registrant’s Second Amended and Restated Bylaws (the “Amended Bylaws”) provide indemnification for its directors and officers to the fullest extent permitted by the DGCL, subject to certain limited exceptions. The Registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the Registrant) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The Amended Charter and Amended Bylaws provide that the Registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the Registrant to procure a judgment in the Registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the Registrant against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

    Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) in the case of a director, for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, (iv) for any transaction from which the director or officer derived an improper personal benefit or (v) in the case of an officer, in connection with any action by or in the right of the corporation. The Amended Charter provides that none of its directors shall be personally liable to the Registrant or to the Registrant’s stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

    The Registrant has entered into separate indemnification agreements with each of its directors and executive officers. Each indemnification agreement provides, among other things, for indemnification to the fullest extent permitted by applicable law and the Amended Charter and Amended Bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements provide for the advancement or payment of all expenses to the indemnitee and for the reimbursement to the Registrant if it is found that such indemnitee is not entitled to such indemnification under applicable law and the Amended Charter and Amended Bylaws.

    The Registrant has also purchased directors’ and officers’ liability insurance for each of its directors and executive officers that covers certain liabilities of directors and officers of the Registrant’s corporation arising

     

    II-2


    out of claims based on acts or omissions in their capacities as directors or officers. Certain of the Registrant’s non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as members of the Registrant’s board of directors.

     

    ITEM 16.

    Exhibits

     

    Exhibit
    Number
      

    Description

      1.1†    Form of Underwriting Agreement
      4.1    Second Amended and Restated Certificate of Incorporation of Aveanna Healthcare Holdings Inc. (filed as Exhibit 3.3 to the Registration Statement on Form S-1, as amended (File No. 333-254981), and incorporated herein by reference).
      4.2    Second Amended and Restated Bylaws of Aveanna Healthcare Holdings Inc. (filed as Exhibit 3.5 to the Registration Statement on Form S-1, as amended (File No. 333-254981), and incorporated herein by reference).
      4.3    Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 4.4 to the registration statement on Form S-1 (File No. 333-254981), filed with the SEC on April 28, 2021).
      4.4    Amended and Restated Stockholders Agreement (incorporated by reference to Exhibit 4.5 to the registration statement on Form S-1 (File No. 333-254981), filed with the SEC on April 28, 2021).
      4.5*    Form of Senior Indenture
      4.6*    Form of Subordinated Indenture
      4.7†    Form of Senior Note
      4.8†    Form of Subordinated Note
      4.9†    Form of Warrant Agreement
      4.10†    Form of Warrant Certificate
      4.11†    Form of Subscription Rights Agreement (including form of rights certificate)
      4.12†    Form of Unit Agreement
      5.1*    Opinion of Greenberg Traurig, LLP
     23.1*    Consent of Greenberg Traurig, LLP (contained in Exhibit 5.1)
     23.2*    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
     24.1*    Power of Attorney
     25.1**    Statement of Eligibility on Form T-1 for Senior Indenture
     25.2**    Statement of Eligibility on Form T-1 for Subordinated Indenture
    107*    Filing Fee Table

     

    *

    Previously filed.

    **

    To be filed, if applicable, separately on Form 305B2 in accordance with the requirements of Section 305(b)(2) of the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and Rule 5b-3 thereunder.

    †

    To be filed by amendment or as an exhibit to a document to be incorporated by reference herein in connection with an offering of the offered securities.

     

    II-3


    ITEM 17.

    Undertakings

     

      (a)

    The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the registration statement is on Form S-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

    (i) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

    (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is

     

    II-4


    part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

    (5) That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

    (i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;

    (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;

    (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of an undersigned Registrant; and

    (iv) Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been, settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

    (d) The undersigned Registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Trust Indenture Act.

     

    II-5


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Pre-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Atlanta, State of Georgia, on September 9, 2024.

     

    AVEANNA HEALTHCARE HOLDINGS INC.
    By:   /s/ Jeff Shaner
      Jeff Shaner
      President, Chief Executive Officer


    Pursuant to the requirements of the Securities Act of 1933, this Pre-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

      

    Title

     

    Date

    /s/ Jeff Shaner

    Jeff Shaner

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      September 9, 2024

    *

    Matthew Buckhalter

      

    Chief Financial Officer

    (Principal Financial Officer)

      September 9, 2024

    *

    Deborah Stewart

      

    Senior Vice President, Chief Accounting Officer

    (Principal Accounting Officer)

      September 9, 2024

    *

    Rodney D. Windley

       Chairman of the Board   September 9, 2024

    *

    Victor F. Ganzi

       Director   September 9, 2024

    *

    Christopher R. Gordon

       Director   September 9, 2024

    *

    Devin O’Reilly

       Director   September 9, 2024

    *

    Sheldon M. Retchin, M.D., M.S.P.H.

       Director   September 9, 2024

    *

    Steven E. Rodgers

       Director   September 9, 2024

    *

    Erica Schwartz, M.D., J.D., M.P.H.

       Director   September 9, 2024

    *

    Robert M. Williams, Jr.

       Director   September 9, 2024

     

    *By:   /s/ Jeff Shaner
    Jeff Shaner
    Attorney-in-Fact
    Get the next $AVAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAH

    DatePrice TargetRatingAnalyst
    12/8/2025Outperform
    William Blair
    11/13/2025$11.00Outperform
    BMO Capital Markets
    9/18/2025$10.00Underweight → Neutral
    Analyst
    8/19/2025$9.50Equal Weight → Overweight
    Barclays
    8/19/2025$8.00Sell → Neutral
    UBS
    7/21/2025$6.00Hold → Buy
    Jefferies
    7/2/2025$5.50Equal Weight
    Barclays
    12/13/2023Neutral → Underweight
    JP Morgan
    More analyst ratings

    $AVAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Aveanna

    William Blair initiated coverage of Aveanna with a rating of Outperform

    12/8/25 8:33:04 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    BMO Capital Markets initiated coverage on Aveanna with a new price target

    BMO Capital Markets initiated coverage of Aveanna with a rating of Outperform and set a new price target of $11.00

    11/13/25 9:12:15 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna upgraded by Analyst with a new price target

    Analyst upgraded Aveanna from Underweight to Neutral and set a new price target of $10.00

    9/18/25 8:32:28 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March

    2/26/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Announces Updated Full Year 2025 and Initial Full Year 2026 Guidance

    ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced updated full year guidance for fiscal year 2025 (year ended January 3, 2026) and its initial full year guidance for fiscal year 2026 (year ending January 2, 2027). Updated Full Year 2025 Guidance (year ending January 3, 2026): For the full fiscal year 2025, we expect to report: Revenue of approximately $2.425 billion to $2.445 billion, updated from greater than $2.375 billion.Net income of approximately $181 million to $220 million.Adjusted EBITDA of approximatel

    1/14/26 8:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna to Participate at the 44th Annual J.P. Morgan Healthcare Conference

    ATLANTA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that its management team will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. Management will present at 9:45 a.m. PST followed by 1x1 investor meetings on the same day, January 14, 2026. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company's website at https://ir.aveanna.com/. The online replay will be available for a limited time shortly following the call. About Aveanna Healthcare Aveanna Healthcare is headquarter

    12/17/25 5:00:00 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Shaner Jeff sold $3,411,399 worth of shares (461,909 units at $7.39), decreasing direct ownership by 15% to 2,650,892 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:16:05 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Chief Compliance Officer Cunningham Patrick A. sold $363,068 worth of shares (49,160 units at $7.39), decreasing direct ownership by 13% to 337,755 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:15:41 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Buckhalter Matthew sold $266,097 worth of shares (36,030 units at $7.39), decreasing direct ownership by 6% to 529,243 units (SEC Form 4)

    4 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    2/19/26 9:15:23 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    SEC Filings

    View All

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    2/27/26 4:30:28 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    2/20/26 4:45:31 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    SEC Form 144 filed by Aveanna Healthcare Holdings Inc.

    144 - Aveanna Healthcare Holdings, Inc. (0001832332) (Subject)

    2/17/26 8:34:03 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    Financials

    Live finance-specific insights

    View All

    Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March

    2/26/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook

    Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year periodThird Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year periodAdjusted EBITDA for Q3 2025 was $80.1 million, a 67.5% increase over the prior year periodIncreased Full Year 2025 Revenue guidance to greater than $2.375 billion, updated from greater than $2.3 billion Increased Full Year 2025 Adjusted EBITDA guidance to greater than $300 million, updated from greater than $270 million ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, hi

    11/6/25 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Announces Third Quarter 2025 Earnings Release Date and Conference Call

    ATLANTA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its third quarter results before the market open on Thursday, November 6, 2025, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13755427. The replay will be available until November 13, 2025.

    10/16/25 6:30:42 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    Leadership Updates

    Live Leadership Updates

    View All

    Aveanna Healthcare Holdings Announces Appointment of New Director

    ATLANTA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Brent Layton to serve as a Class III director of the Board of Directors of Aveanna Healthcare Holdings Inc., and additionally as a member of the Audit Committee of the Board, effective November 1, 2024. "I am delighted to announce the appointment of Brent Layton to our Aveanna Board of Directors. Brent brings a wealth of healthcare knowledge from over 20 years of leadership at Centene Corporation. Brent's experience working with state and feder

    11/4/24 7:30:02 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Announces Appointment of Chief Legal Officer and Secretary

    ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Jerry Perchik to serve as Chief Legal Officer and Secretary, effective April 29, 2024. "I am pleased to announce the appointment of Jerry to the Chief Legal Officer and Secretary role. Jerry has a strong background in corporate law and a wealth of healthcare industry and regulatory experience. I have known Jerry for more than a decade and have great trust in his leadership and counsel. It is a pleasure to welcome Jerry to our Aveanna family, and

    4/3/24 6:30:06 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Announces Appointment of Chief Financial Officer

    ATLANTA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Matt Buckhalter to serve as Chief Financial Officer and continuing in the role of Principal Financial Officer, effective January 1, 2024. Mr. Buckhalter was appointed to serve as Interim Chief Financial Officer and Principal Financial Officer in July, 2023. "I am pleased to announce the promotion of Matt to the Chief Financial Officer position. Matt has provided strong financial leadership and continuity as we build on our recent successes to t

    12/11/23 7:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aveanna Healthcare Holdings Inc.

    SC 13G - Aveanna Healthcare Holdings, Inc. (0001832332) (Subject)

    2/14/24 4:00:42 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by Aveanna Healthcare Holdings Inc.

    SC 13G - Aveanna Healthcare Holdings, Inc. (0001832332) (Subject)

    2/14/22 6:43:51 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care